<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00204568</url>
  </required_header>
  <id_info>
    <org_study_id>jth_001</org_study_id>
    <nct_id>NCT00204568</nct_id>
  </id_info>
  <brief_title>Trofosfamide Versus Adriamycin in Elderly Patients With Soft Tissue Sarcoma (STS)</brief_title>
  <official_title>Randomized Phase II Trial of Trofosfamide vs. Adriamycin in Elderly Patients With Previously Untreated Metastatic Soft Tissue Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Schleswig-Holstein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Arbeitsgemeinschaft fur Internistische Onkologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Sarcoma Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>French Sarcoma Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Schleswig-Holstein</source>
  <brief_summary>
    <textblock>
      The goal of this trial is to determine whether oral continuous (metronomic) therapy with
      trofosfamide results in a similar rate of progression-free time after 6 months as intravenous
      treatment with adriamycin. In addition, the study is intended to investigate the level of
      toxicity associated with the two treatment regimens (safety profile).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Group A:Adriamycin (60 mg/m2, d1, qd22) 75 mg/m2 may be applied instead of 60 mg/m2 for
      patients between 60 and 70 years of age (optional) Group B:Trofosfamide (300 mg absolute p.o.
      qd over 7 days, then 150 mg p.o. absolute qd continuously) In case of absence of any toxicity
      during treatment with trofosfamide 150 mg absolute a dose escalation to 200 mg absolute is
      allowed (optional)
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 2004</start_date>
  <completion_date type="Anticipated">October 2013</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival after 6 months</measure>
    <time_frame>after 6 months</time_frame>
    <description>Progression-free survival after 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Grade III/IV toxicity Objective remission rate according to RECIST criteria Overall survival • Quality of life according to EORTC QLQ-30</measure>
    <description>Grade III/IV toxicity Objective remission rate according to RECIST criteria Overall survival Quality of life according to EORTC QLQ-30</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">117</enrollment>
  <condition>Sarcoma, Soft Tissue</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adriamycin mono</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trofosfamide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adriamycin</intervention_name>
    <description>60 mg/m2, d1, W d22</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trofosfamide</intervention_name>
    <description>300 mg absolute d1-7, followed by 150 mg absolute continuously</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically established metastatic (N+ or M1 = stage IV) or non-resectable soft
             tissue sarcoma·

          -  Grading II/III (Guillou et al. J Clin Oncol 1997)

          -  At least 1 measurable tumor parameter according to RECIST criteria

          -  Evidence of progression or primary manifestation (except osseous metastases and
             pleural effusion)

          -  No previous radiation therapy of the only measurable lesion

          -  No previous chemotherapy for metastatic disease; previous adjuvant chemotherapy is
             permitted if there was no progression of the disease within a period of 6 months

          -  Patients aged 60 years and beyond

          -  Written patient informed consent

          -  ECOG Status 0-2

          -  Granulocytes &gt;= 2 x 10**9/l and thrombocytes &gt;= 100 x 10**/l

          -  Serum creatinine, bilirubin &lt; 1.5 times the upper limit of normal value, albumin &gt; 25
             g/l

          -  No severe comorbidity including psychosis or any previous history of uncontrolled
             cardiovascular disease

          -  Normal left-ventricular function by echocardiography or MUGA scan

          -  No symptomatic CNS metastases

          -  Willingness to receive regular follow-up examinations

        Exclusion Criteria:

          -  Histological grading of malignancy: G I

          -  Histology of gastrointestinal stromal tumor, chondrosarcoma, uterine stromal sarcoma,
             mesothelioma, neuroblastoma, osteosarcoma, Ewing´s sarcoma/PNET, desmoplastic round
             cell tumor, embryonal rhabdomyosarcoma, alveolar soft tissue sarcoma

          -  Less than 5 years free of secondary malignancy except adequately treated carcinoma in
             situ (CIS) of the cervix, the bladder urothelium, basal cell carcinoma, or adenoma of
             the colon including pTIS, pTIN
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joerg T. Hartmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center , Comprehensive Cancer Center North, Christian-Albrechts-University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Center , Comprehensive Cancer Center North, Christian-Albrechts-University</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>January 7, 2013</last_update_submitted>
  <last_update_submitted_qc>January 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Schleswig-Holstein</investigator_affiliation>
    <investigator_full_name>J. T. Hartmann</investigator_full_name>
    <investigator_title>Prof. Dr. med. J. T. Hartmann</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Trofosfamide</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

